We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Project Improving Biotherapeutic Workflows Highlighted at BioProcess Conference
Product News

Project Improving Biotherapeutic Workflows Highlighted at BioProcess Conference

Project Improving Biotherapeutic Workflows Highlighted at BioProcess Conference
Product News

Project Improving Biotherapeutic Workflows Highlighted at BioProcess Conference


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Project Improving Biotherapeutic Workflows Highlighted at BioProcess Conference"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, has announced its line-up of activities during the BioProcess International (BPI) Conference, being held during Biotech Week Boston in September.

The focus will be on its newest facility, located in greater Boston in Milford, MA, and the new projects taking place there, including multi-specific antibodies. The site will support both clinical and commercial manufacturing programs as the projects advance through development.

Dr. Jesús Zurdo, Senior Vice President Innovation and Venture Partnerships, added: “At Rentschler Biopharma, we are working to improve our processes and implement new technologies with the goal of enabling better, faster, more cost-effective development and production for our clients. The integration of the methodologies being presented at BPI with faster cell line development workflows and streamlined fit-for-purpose process development could dramatically transform overall biotherapeutic development timelines and increase bioprocessing efficiency.”


Advertisement